Opinion|Videos|July 18, 2024
TARGET-DERM: A Real-World Study of Patient-Reported Outcomes in Atopic Dermatitis
Author(s)Shawn Kwatra, MD
An expert on skin conditions provides an overview of TARGET-DERM, a real-world study of patient-reported outcomes in atopic dermatitis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Can you discuss recently presented data from TARGET-DERM, a longitudinal, observational study, on the effect of skin severity and itch (both independent and combined) on patients’ QoL (RAD 2024 meeting)?
- What do these data mean for clinicians?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
4
Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study
5